Hepatitis B virus reactivation is always potential risk in HBV-naïve patients receiving donor organs with evidence of past HBV infection. Lifelong NA prophylaxis should recommend in such recipient. 2017; 28: 518-21
Turk J Gastroenterol
ABSTRACTThe morbidity and mortality of hepatitis B virus-related liver disease are linked to the persistence of the hepatitis B virus replication. Viral suppression with antiviral therapy has been shown to provide clinical benefits. Several special groups of patients with hepatitis B virus infection require special attention. In this brief report, based on European Association for the Study of the Liver 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection, the current optimal management of special patient groups with hepatitis B virus infection is summarized.